Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-02-05, Stock:NVS, The news for the past five days is as follows:
2020-01-29: NEWS1: Novartis Edges Higher Into Buy Zone Even As Generic Drugs Struggle.NEWS2: Rockville biotech opens new HQ as it goes on hiring spree.NEWS3: Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal.NEWS4: Novartis (NVS) Earnings and Revenues Miss Estimates in Q4.NEWS5: Novartis Stock Is Rising as Earnings Inch Past Forecasts.NEWS6: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut.NEWS7: Novartis Earnings Narrowly Top; Drug Giant Rises In Buy Zone.NEWS8: Novartis says taxes hit fourth-quarter profit, but sees growth in 2020.NEWS9: Novartis sees no coronavirus disruption amid China growth.NEWS10: Novartis sales rise 9% as new medicines provide a boost.NEWS11: Novartis predicts rising sales and minimal disruption from coronavirus.NEWS12: Novartis/Big Pharma: dosing up.
2020-01-30: NEWS1: Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drug.NEWS2: Biogen Stock Gets a Lift From Strong Earnings Report.NEWS3: Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs.
2020-01-31: NEWS1: Top Stock Analyst Reports for Microsoft, Facebook & Novartis.NEWS2: Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative.NEWS3: Is Biogen Stock A Buy As It Pivots Back Into Alzheimer's Disease?.NEWS4: European stocks head for worst week since October amid coronavirus and growth worries.
2020-02-03: NEWS1: Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?.NEWS2: The Zacks Analyst Blog Highlights: Microsoft, Facebook, Novartis, Tesla and Raytheon.
2020-02-04: NEWS1: Eaton Vance Exits Celgene, Trims Amgen Position.NEWS2: A Pick and Shovel Strategy to Avoid Competition and Speculation.NEWS3: Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal.NEWS4: Analysts Forecast Huge Upsides for Aimmune, Biohaven.

Answer: Rise